Correction to “High affinity antagonists of the vanilloid receptor”


Some authors were inadvertently omitted from the article. The complete and correct list of authors and affiliations is as follows:

Yun Wang, Tama Szabo, Jacqueline D. Welter, Attila Toth, Richard Tran, Jiyoun Lee, Sang Uk Kang, Yong-sil Lee, Kyung Hoon Min, Young-Ger Suh, Mi-kyung Park, Hyeung-geun park, Young-Ho Park, Hee-Doo Kim, Uhtaek Oh, Peter M. Blumberg, and Jeewoo Lee

National Cancer Institute, Bethesda, Maryland (Y.W., T.S., J.D.W., A.T., R.T., P.M.B.); College of Pharmacy, Seoul National University, Seoul, Korea (Ji.L., S.U.K., Y.L., K.H.M., Y.-G.S., M.P., H.P., U.O., Je.L.), Sookmyung Women's University, Seoul, Korea (H.-D.K.); Amore Pacific Corp., R&D Center, Yongin, Korea (Y.-H.P.)

On pages 948 (left column, last line) and 954 (right column, line 38), patents WO 02/16317, WO 02/16318, and WO 02/16319 should be cited as references for the series of derivatives that function as rVR1 antagonists. Full information for these patents is provided below:


Finally, KJM429 and JYL1421 correspond to the compound designations MK056 and SC0030 (Fig. 1) in the above patents.

The authors regret these errors and apologize for any confusion or inconvenience they may have caused.